Controversies on HDL: Should it Be a Target Biomarker in Patients With Lipid Disorders?

Controversies on HDL: Should it Be a Target Biomarker in Patients With Lipid Disorders? Curr Vasc Pharmacol. 2013 Apr 25; Authors: Nicholls S Abstract LDL cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of HDL may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as towhether attempts to target HDL will be of clinical benefit or futility. PMID: 23627977 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research